Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1): Implications for an integrated model of MEN-1 tumorigenesis

Cancer

Volumn 86, Issue 10, 1999, Pages 2154-2159

  Burgess, John R ^a   Greenaway, Tim M ^a   Parameswaran, Venkateswaran ^a   Shepherd, Joseph J ^b  

^a ROYAL HOBART HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Carcinoid; Gastrinoma; Malignancy; Multiple endocrine neoplasia type I (MEN 1); Octreotide

Indexed keywords

GASTRIN; OCTREOTIDE;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFECT; FATIGUE; FEMALE; GASTRIN BLOOD LEVEL; GASTRIN RELEASE; HUMAN; HYPERGASTRINEMIA; LETHARGY; LIVER METASTASIS; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS CANCER; PARATHYROID TUMOR; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GASTRINS; GASTROINTESTINAL NEOPLASMS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; OCTREOTIDE; PANCREATIC NEOPLASMS;

EID: 0033571265     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<2154::AID-CNCR39>3.0.CO;2-W     Document Type: Article

References (29)

1. Marx S, Spiegel AM, Skarulis M, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998;129:484-94.
2. Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN 1). Q J M 1996; 89:653-69.
3. Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN 1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998;243:465-70.
4. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;322:85-7.
5. Padberg B, Schroder S, Capella C, Frilling A, Kloppel G, Heitz PU. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch 1995;426:541-8.
6. Wilkinson S, Teh B, Davey K, McArdle JP, Young M, Shepherd JJ. Cause of death in multiple endocrine neoplasia syndrome type 1. Arch Surg 1993;128:683-90.
7. Burgess JR, Greenaway TM, Parameswaran V, Challis DR, David R, Shepherd JJ. Enteropancreatic malignancy in MEN 1-risk factors and pathogenesis. Cancer 1998;83:428-34.
8. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. N Engl J Med 1990;322:723-7.
9. Solcia E, Capella C, Fiocca E, Rindi G, Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990;14:503-13.
10. Bordi C, D'Adda T, Azzoni C, Pilato FP, Caruana P. Hypergastrinemia and gastric enterochromaffin like cells. Am J Surg Pathol 1995;19(Suppl 1):S8-19.
11. MacFarlane MP, Fraker DL, Alexander HR, et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995;118:973-9.
12. Veldhuis JD, Norton JA, Wells SA, Viniki AI, Perry RR. Surgical versus medical management of multiple endocrine neoplasia (MEN) type 1. J Clin Endocrinol Metab 1997;82: 357-64.
13. Wynick D, Bloom SR. Clinical review 23. The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991;73:1-3.
14. Burgess JR, Shepherd JJ, Murton F, Parameswaran V, Greenway TM. Effective control of bone pain by ocredtreotide in a patient with metastatic gastrinoma. Med J Aust 1996;164: 725-7.
15. Shepherd JJ. The natural history of multiple endocrine neoplasia type 1: highly uncommon or highly unrecognised? Arch Surg 1991;126:935-52.
16. Le Bodic MF, Heymann MF, Lecomte M, Berger N, Berger F, Louvel A, et al. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type 1. Am J Surg Pathol 1996;20:1378-84.
17. Ferraro G, Annibale B, Marignani M, Azzoni C, D'Adda T, D'Ambra G, et al. Effectiveness of octreotide in controlling fasting hypergastrinaemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 1996;81:677-83.
18. Pitot HC. The molecular biology of carcinogenesis. Cancer 1993;72:962-70.
19. Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1 - associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer 1997;57:2238-43.
20. Dong Q, Debelenko LV, Chandrasekharappa SC, Emmert-Buck MR, Zhuang Z, Guru SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1997;82:1416-20.
21. Brandi ML, Falchetti A, Tonelli F, Bordi C. Are allelic losses at 11q13 universal in MEN 1 tumours? J Clin Endocrinol Metab 1996;81:3162-3.
22. Skogseid B, Rastad J, Gobl A, Larsson C, Backlin K, Juhlin C, et al. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 1995;118:1077-82.
23. Modlin I, Kumar R, Soroka C, Ahlman H, Nilsson O, Goldenring JR. Histamine as an intermediate growth factor in genesis of gastric ECLomas associated with hypergastrinaemia in mastomys. Dig Dis Sci 1994;39:1446-53.
24. Brandi ML, Marx SJ, Aurbach GD, Fitzpatrick LA. Familial multiple endocrine neoplasia type 1: a new look at pathophysiology. Endocr Rev 1987;8:391-405.
25. Zaniewski M, Jordan PH Jr., Yip B, Thornby JI, Mallette LE. Serum gastrin level is increased by chronic hypercalcemia of parathyroid or nonparathyroid origin. Arch Intern Med 1986; 146:478-82.
26. Bordi C, Falchetti A, Buffa R, Azzoni C, D'Adda T, Caruana P, et al. Production of basic fibroblast growth factor by gastric carcinoid tumors and their putative cells of origin. Hum Pathol 1994;25:175-80.
27. Norton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type 1: a prospective study. Surgery 1987:102:958-66.
28. Burgess J, David R, Parameswaran V, Greenaway TM, Shepherd JJ. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in Multiple Endocrine Neoplasia Type 1. Arch Surg 1998;133:126-9.
29. Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med 1995; 238:269-80.